Astellas GU Masterclass: PADCEV

Friday 11 July 2025, 18:30–20:15 KST

Saturday 12 July 2025, 08:30–13:00 KST

Urothelial Carcinoma

Faculty highlights video

Dr Alejo Rodríguez-Vida, Spain
Prof. Daniel Petrylak, United States
Dr Niara Oliviera, Australia
Prof. Yüksel Ürün, Turkey

Plenary slides

Welcome and introduction from Chair

Prof. Sang Joon Shin, South Korea
10 minutes

The Chair provides an overview of the objectives and agenda for the meeting

padcev
Session 1 - Setting the scene: Understanding the LA/mUC treatment landscape

Dr Alejo Rodríguez-Vida, Spain

Prof. Daniel Petrylak, United States
30 minutes

The evolution of the treatment landscape in advanced urothelial carcinoma, including recent data updates and how these have led to changes in clinical guidelines

padcev
Session 2 - Revision and reflection: Assessing the impact of recent changes in the LA/mUC treatment landscape

Dr Alejo Rodríguez-Vida, Spain
Prof. Daniel Petrylak, United States
Dr Kaiwei Yang, China
60 minutes

The impact of recent data updates and development of ADCs on the LA/mUC treatment landscape, including RWE, long-term data and sub-analyses, strategies for achieving optimal treatment outcomes for patients

padcev
Breakout room 1 - On the horizon: Recent data for 2L treatment for patients with unresectable LA/mUC

Dr Niara Oliveira (Moderator), Australia
Dr Alejo Rodríguez-Vida, Spain
Dr Ashok Kumar Vaid, India
Dr Mark Igorevich Gluzman, Russian Federation
45 minutes

The evolution of the 2L treatment landscape in advanced urothelial carcinoma, including the limitations of previous therapies, a summary of recent RWE data updates & a discussion of strategies for optimal treatment outcomes with EV monotherapy

padcev
Breakout room 2 – On the horizon: Recent data for 1L standard of care treatment of unresectable LA/mUC

Prof. Daniel Petrylak (Moderator), United States
Dr Ye YAN, China
Prof. Eun Hee Jung, South Korea
45 minutes

The evolution of the 1L treatment landscape in advanced urothelial carcinoma, including the limitations of previous therapies, a summary of recent EV-302 data updates & a discussion of strategies for optimal treatment outcomes with EV+P

padcev
Breakout room 1– Best practice sharing: Practical approaches to patient care in 2L treatment

Dr Alejo Rodríguez-Vida (Moderator), Spain
Dr Phichai Chansriwong, Thailand
Prof. Yüksel Ürün, Turkey
1h 45 minutes

Best practice sharing of clinical outcomes from real clinical practice demonstrating optimal treatment strategy, including effective AE management, of EV monotherapy as 2L treatment for patients with advanced LA/mUC

padcev
Breakout room 2 – Best practice sharing: Practical approaches to patient care in 1L treatment

Prof. Daniel Petrylak (Moderator), United States
Prof. Jungmin Jo, South Korea
Dr Jiun-I Lai, Taiwan
1h 45 minutes

Best practice sharing of clinical outcomes from real clinical practice demonstrating optimal treatment strategy, including effective AE management, of EV+P as 1L treatment for patients with advanced LA/mUC

padcev
Session 3 - Principles of AE management with standard of care

Dr Niara Oliveira (Moderator), Australia
Prof. Daniel Petrylak, United States
Dr Johan Chan, Singapore
Dr Kirsten Yeo, Singapore
60 minutes

Sharing of practical techniques for managing patients who are receiving treatment with EV effectively in clinical practice, including managing and balancing the impact of treatment, AEs and patient quality of life

padcev
Session 4 - Principles of AE management with standard of care: Ask the experts

All Faculty
20 minutes

Best practice sharing between global experts and HCPs, driving optimal patient care

padcev

Prescribing Information

Prescribing Information is available for PADCEV® (enfortumab vedotin) 20mg (here) and 30mg (here). This promotional meeting is fully sponsored and supported by Astellas, including speaker-related honoraria and production of materials. It is intended for healthcare professionals only.

PADCEV indications:

  • EV as first-line therapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. Combination therapy with pembrolizumab.
  • EV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 or programmed death-ligand 1 inhibitor, and have received a platinum-containing chemotherapy

Please refer to the Korean PI for PADCEV® (enfortumab vedotin) via the following QR Code:

PADCEV 20mg

PADCEV 20mg

PADCEV 30mg

PADCEV 30mg

AE reporting information

Adverse events should be reported.

For Korea, healthcare professionals are asked to report any suspected adverse reactions to Astellas Pharma Korea. Inc
(Address: 7F Parnas tower, 521, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea; Telephone: +82 10 5254 3389; Email: safety-kr@kr.astellas.com)

1L, first line; 2L, second line; ADC, antibody-drug conjugate; AE, adverse event; EV, enfortumab vedotin; GU, genitourinary; LA/mUC, locally advanced/metastatic urothelial carcinoma; P, pembrolizumab; RWE; real-world evidence.